At the news
? BULLISHIMPACT 6/10 8-K filed Nov 5, 2026 at 07:05 ET
Iovance Biotherapeutics reported record Q3 2026 revenue of ~$122M, up ~80% YoY, with gross margin improving to ~60%. The company maintained its FY26 revenue guidance of $410M-$420M and highlighted positive clinical data in NSCLC and sarcoma. Cash position of ~$382M is expected to fund operations well into 2029.
- Q3 2026 total product revenue of ~$122M, up ~80% from ~$67M in Q3 2025 and ~22% from ~$99M in Q2 2026
- U.S. Amtagvi revenue of ~$102M, up ~77% YoY and ~12% sequentially
- Gross margin of ~60%, up from 56% in Q2 2026
- R&D expenses decreased ~16% sequentially, marking fifth straight quarter of improvement
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access